CA2598786A1 - Composition and method for increasing the anabolic state of muscle cells - Google Patents
Composition and method for increasing the anabolic state of muscle cells Download PDFInfo
- Publication number
- CA2598786A1 CA2598786A1 CA002598786A CA2598786A CA2598786A1 CA 2598786 A1 CA2598786 A1 CA 2598786A1 CA 002598786 A CA002598786 A CA 002598786A CA 2598786 A CA2598786 A CA 2598786A CA 2598786 A1 CA2598786 A1 CA 2598786A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- dissolution
- composition
- phase
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 12
- 238000000034 method Methods 0.000 title claims abstract 11
- 230000001195 anabolic effect Effects 0.000 title 1
- 210000000663 muscle cell Anatomy 0.000 title 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims abstract 7
- 229940117360 ethyl pyruvate Drugs 0.000 claims abstract 7
- 239000002207 metabolite Substances 0.000 claims abstract 6
- 210000003205 muscle Anatomy 0.000 claims abstract 4
- 239000004615 ingredient Substances 0.000 claims abstract 3
- 238000004090 dissolution Methods 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- IGIDLTISMCAULB-UHFFFAOYSA-N 3-methylvaleric acid Chemical compound CCC(C)CC(O)=O IGIDLTISMCAULB-UHFFFAOYSA-N 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000005693 branched-chain amino acids Chemical class 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one .alpha.-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.
Claims (18)
1. A composition for causing an anabolically-favorable state for muscle in a mammal, comprising from about 0.0001 g to about 0.75 g of ethyl pyruvate and from about 0.00001 g to about 0.75 g t of at least one .alpha.-hydroxy branched-chain amino acid metabolite.
2. The composition of claim 1, wherein the .alpha.-hydroxy branched-chain amino acid metabolite is selected from the group consisting of .alpha.-hydroxyisocaproic acid, .alpha.-hydroxy,.beta.-methylvaleric acid, and .alpha.-hydroxy-isovaleric acid.
3. The composition of claim 2, wherein the amount of the ethyl pyruvate is about 0.001 g; and the amount of the .alpha.-hydroxyisocaproic acid is about 0.0001 g.
4. The composition of claim 2 wherein at least a portion of one or more ingredients is fine-milled.
5. The composition of claim 2 wherein the ethyl pyruvate and the .alpha.-hydroxy branched-chain amino acid metabolite are part of a solid oral dosage form having a multi-phasic rate of dissolution.
6. The composition of claim 5 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.
7. The composition of claim 6, wherein the multi-phasic rate of dissolution provides a time-release mechanism.
8. The composition of claim 6, further comprising a third-phase, whereby said third-phase has a third rate of dissolution.
9. The composition of claim 8, wherein the multi-phasic rate of dissolution provides a time-release mechanism.
10. A method for causing an anabolically-favorable state of muscle in a mammal, comprising at least the step of administering to the mammal a composition comprising from about 0.0001 g to about 0.75 g of ethyl pyruvate and from about 0.00001 g to about 0.75 g at least one .alpha.-hydroxy branched-chain amino acid metabolite.
11. The method of claim 10, wherein the .alpha.-hydroxy branched-chain amino acid metabolite is selected from the group consisting of .alpha.-hydroxyisocaproic acid, .alpha.-hydroxy-.beta.-methylvaleric acid, and .alpha.-hydroxy-isovaleric acid.
12. The method of claim 11, wherein the amount of the ethyl pyruvate is about 0.001 g; and the amount of the .alpha.-hydroxyisocaproic acid is about 0.0001 g.
13. The method of claim 11 wherein at least a portion of one or more ingredients is fine-milled.
14.The method of claim 11 wherein the ethyl pyruvate and the .alpha.-hydroxyisocaproic acid are part of a solid oral dosage form having a multi-phasic rate of dissolution.
15.The method of claim 14 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.
16.The method of claim 15, wherein the multi-phasic rate of dissolution provides a time-release mechanism.
17.The method of claim 15, further comprising a third-phase, whereby said third-phase has a third rate of dissolution.
18.The method of claim 17, wherein the multi-phasic rate of dissolution provides a time-release mechanism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2598786A CA2598786C (en) | 2007-09-11 | 2007-09-11 | Composition and method for increasing the anabolic state of muscle cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2598786A CA2598786C (en) | 2007-09-11 | 2007-09-11 | Composition and method for increasing the anabolic state of muscle cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2598786A1 true CA2598786A1 (en) | 2008-12-16 |
| CA2598786C CA2598786C (en) | 2012-01-03 |
Family
ID=40134902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2598786A Expired - Fee Related CA2598786C (en) | 2007-09-11 | 2007-09-11 | Composition and method for increasing the anabolic state of muscle cells |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2598786C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021198788A1 (en) * | 2020-03-30 | 2021-10-07 | Compagnie Gervais Danone | Fermented milk compositions for use in methods of nutritional supplementation |
-
2007
- 2007-09-11 CA CA2598786A patent/CA2598786C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021198788A1 (en) * | 2020-03-30 | 2021-10-07 | Compagnie Gervais Danone | Fermented milk compositions for use in methods of nutritional supplementation |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2598786C (en) | 2012-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203101B2 (en) | Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability | |
| CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JP2020504108A (en) | Amino acid composition and method for treating liver disease | |
| RU2006132719A (en) | METHOD FOR INCREASING THE BIOLOGICAL ACCESSIBILITY OF OSPEMIFEN | |
| EP1283054A4 (en) | Drugs for complications of diabetes and neuropathy and utilization thereof | |
| FI3782612T3 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| MXPA05009933A (en) | Compositions comprising fatty acids and amino acids. | |
| HK1080689A1 (en) | Compositions comprising short and long chain fattyacids and methods of their use for the management of body weight | |
| EP1750862A4 (en) | Pharmaceutical composition containing irbesartan | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| RU2009126767A (en) | 1-Phenyl-1-thio-d-glucitol derivative | |
| NO20050667L (en) | N-substituted-1H-indole-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes | |
| WO2007056264A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally | |
| RU2009111391A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING hGH FOR ORAL ADMINISTRATION | |
| JP2007238598A5 (en) | ||
| RU2007138582A (en) | ORAL DOSAGE FORMS OF HEMCITABINE DERIVATIVES | |
| CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
| HK1129071A1 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
| WO2004071156A3 (en) | Use of edible acid in fast-dispersing pharmaceutical solid dosage forms | |
| JP5048372B2 (en) | Hair growth promoter | |
| CA2598786A1 (en) | Composition and method for increasing the anabolic state of muscle cells | |
| SE9903611D0 (en) | Novel compounds III | |
| RU2353358C2 (en) | Pregabalin derivatives for hot flush treatment | |
| WO2005056520A8 (en) | Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy | |
| WO2007042983A3 (en) | Fluridone as an anti-inflammatory agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220912 |